epocrates logo
epocrates logo
epocrates logo
  • 0

Interaction Check

epocrates logo

Sign in to access our clinical decision support tools

Sign in Create Account

Selected Drugs Clear All

  • remove Journavx
    suzetrigine
  • remove Paxlovid
    nirmatrelvir and ritonavir

multicheck MultiCheck Results - 2 Interactions

Smiley face Smiley face

Contraindicated

Smiley face Smiley face Journavx (suzetrigine) + Paxlovid (nirmatrelvir and ritonavir)

Contraindicated


suzetrigine + ritonavir

contraindicated: combo may incr. suzetrigine and active metabolite levels, risk of adverse effects; may decr. ritonavir levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

Caution Advised


suzetrigine + nirmatrelvir

caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

Additional Considerations

Smiley face Smiley face nirmatrelvir in Paxlovid

patients on ritonavir- or cobicistat-containing HIV or HCV regimens may continue their tx as indicated

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information